benzyl 2-(5-(4-methoxyphenyl)-4-(3-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)acetate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: benzyl 2-(5-(4-methoxyphenyl)-4-(3-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)acetate
• 英文别名: Benzyl 2-[[5-(4-methoxyphenyl)-4-[3-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]sulfanyl]acetate
• 化学式: C₂₅H₂₀F₃N₃O₃S
• 分子量: 499.513
• InChiKey: HADOTABIARHPOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  91.5
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS
  申请人：Jung Birgit

  公开号：US20100099651A1

  公开（公告）日：2010-04-22

  The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK 1 antagonists, anticholinergics and endothelin antagonists, processes for preparing the compositions and the use thereof as medicament in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes.